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In recent years, it has been well established that a dynamic
interaction between the skin and the nervous system plays an
important role in both skin homeostasis and cutaneous disease.
Neuropeptides released from the network of unmyelinated nerve
®bers in the skin can interact with speci®c receptors on cutaneous
cells including keratinocytes, Langerhans cells, melanocytes,
microvascular endothelial cells, and mast cells to mediate a cascade
of in¯ammatory and proliferative activities. While many investi-
gators have focused on studying the role of neuropeptides secreted
from sensory nerve ®bers, it is clear that other neurotransmitters
and their receptors are also operative in the skin in ways that have
yet to be fully understood.
In this issue, there are three papers that further demonstrate the
importance of small proteins, primarily thought to be neurotrans-
mitters, in mediating a variety of biological activities in the skin.
Merighi et al examine the role of adenosine receptors in the
proliferation and cell death of cultured human melanoma cells.
Adenosine has been reported to display a variety of contradictory
biological effects including both the induction and inhibition of cell
proliferation as well as pro-apoptotic and cytoprotective effects in
different situations. Furthermore, adenosine affects the immune
system by exerting immunosuppressive and anti-in¯ammatory
activities. Using the cultured A375 human melanoma cell line,
these studies attempt to sort out how adenosine could both
promote the growth and proliferation of tumor cells as well as
induce cell death. The answer may in part be due to the relative
expression of different adenosine receptors on the malignant
melanoma cells. Four different adenosine receptors have been
identi®ed and pharmacologically characterized: A1, A2A, A2B, and
A3. These receptors are seven trans-membrane glycoprotein
coupled G protein receptors that are widely distributed on different
tissues. A2A and A2B receptors are coupled to adenylate cyclase
activity and their stimulation increases intracellular cAMP con-
centrations. A1 and A3 receptor stimulation decreases cAMP
concentration and raises intracellular Ca2++ levels by a pathway
involving PLC activation. It was determined that treatment of the
A375 melanoma cells with an A2A speci®c agonist led to cell death,
whereas the A3 receptor agonists had a cytoprotective effect. This
basic observation may help explain the apparent con¯icting effects
of adenosine on malignant melanoma cells by the activation of the
A2A and/or A3 adenosine receptors. The authors hypothesize that
increased extracellular adenosine is released in tumors such as
melanoma due to localized hypoxia, tissue in¯ammation, and cell
death. The increased peritumoral adenosine could then facilitate
tumor progression by acting as an immunosuppressant agent and a
cytoprotective agent in tumor cells expressing high relative levels of
the A3 adenosine receptor compared to the A2A receptor. It is
proposed that this observation may lead to the development of a
potentially novel class of pharmacological agents to target a variety
of different tumor types with speci®c adenosine receptors.
In a related paper, Slominski et al further examine the
neuroendocrine activities in the skin. This group and others have
identi®ed the presence of various neuroendocrine factors in the
skin that have commonly been associated with the systemic
response to stress, including the proopiomelanocortin (POMC)-
derived peptides MSH, ACTH, and (-endorphin, corticotropin-
releasing hormone (CRH) and urocortin. Speci®cally, this paper
presents a series of studies to determine if the skin expresses the
enzymes required for serotonin biosynthesis and/or metabolism.
Serotonin has powerful vasodilator, immunomodulator, and
growth factor actions. In this study, Slominski's laboratory found
that hamster skin and melanoma cells express the genes required for
the synthesis and metabolism of serotonin. Although it has been
appreciated for a number of years that serotonin is an important
neuromediator in the central nervous system and some peripheral
tissues, its role in modulating various biological processes in the skin
remains to be determined.
In a third paper in this issue, Haberberger et al examine the
cholinergic system in the skin. Speci®cally, they present a series of
studies in which they examine the expression of the high-af®nity
choline transporter (CTH1) in the HaCaT keratinocyte cell line
and in human skin. The skin contains elements of the neuronal and
a non-neuronal cholinergic system. Eccrine sweat glands receive
cholinergic nerve ®bers, and keratinocytes have been found to
synthesize and release acetylcholine (Ach). The uptake of choline is
the rate-limiting step in Ach synthesis and requires a transporter to
enter the cells. It has been proposed that CHT1 is unique to
cholinergic neurons but not non-neuronal tissues. This paper for
the ®rst time demonstrates the localization and distribution of the
high af®nity choline transporter, CHT1, in the skin of man and rat.
In addition to nerve ®bers, CHT1 is present in non-neuronal
structures such as keratinocytes of the epidermis and hair shafts.
Therefore, this study supports the presence of a choline recycling
pathway in keratinocytes similar to that found in neurons. Since
previous work indicates that keratinocytes are also capable of
synthesizing, processing, and releasing Ach, the epidermis is fully
capable of localized production of this potent neuromediator
independent of the neurological system. These studies therefore
extend our knowledge of the neurobiological capacity of the skin
by both cutaneous neuronal and non-neuronal cells in the skin.
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